慢性透析患者における水素含有透析液を用いた血液透析の臨床的影響：12ヶ月観察の中間解析
A prospective observational study enrolled 262 chronic hemodialysis patients (140 receiving hydrogen-enriched dialysate at 30–80 ppb; 122 receiving conventional dialysate) and followed them for 12 consecutive months without hospitalization. Standard dialysis-related laboratory and physical parameters did not differ significantly between groups. However, the hydrogen-enriched group showed lower defined daily doses of antihypertensive medications and lower rates of self-reported severe fatigue and pruritus. Multivariate analysis confirmed that hydrogen-enriched hemodialysis was an independent predictor of reduced antihypertensive drug use and the absence of severe fatigue and pruritus at 12 months, after adjustment for potential confounders. These findings suggest that delivering molecular hydrogen via dialysate may confer clinical benefits beyond those achieved with conventional hemodialysis, providing a rationale for further controlled trials.
Molecular hydrogen is proposed to exert anti-inflammatory and antioxidant effects, potentially mitigating the elevated oxidative stress and systemic inflammation characteristic of chronic dialysis patients, thereby contributing to improvements in subjective symptoms and reduced antihypertensive medication requirements.
Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).
See also:
https://h2-papers.org/en/papers/28902900